Table 2.
Characteristics of aptasensors for human viral diagnostic purposes
Target | Aptamer | Kd | Detection method | Transducer | Assay time | LOD | Ref. |
---|---|---|---|---|---|---|---|
SARS coronavirus | |||||||
Nucleocapsid protein (C-terminal) | RNA | 1.65 nM | Chemiluminescence immunosorbent assay (CLISA) | Optical | ±8 hours | 20 pg/mL | [45] |
Nucleocapsid protein (C-terminal) | RNA | 1.65 nM | Nanoarray aptamer chip | Mass | ±6 hours | 2 pg/mL | [45] |
Nucleocapsid protein | DNA | 4.93 ± 0.30 nM | Western blot | Optical | NA | NA | [44] |
Influenza virus | |||||||
Hemagglutinin + virion H5N1 | DNA | 4.65 nM | Surface plasmon resonance (SPR) | Optical | 1.5 hours | 0.128 HAU | [74] |
Hemagglutinin H5N1 | DNA | 4.65 nM | Hydrogel-based quartz crystal microbalance (QCM) | Mass | 30 minutes | 0.0128 HAU | [64] |
Hemagglutinin H5N1 | DNA | NA | Bio-nanogate | Electrochemical | 1 hour | 2.10−3 HAU | [79] |
Polyvalent anti-influenza nucleoprotein | DNA | NA | Surface enhanced Raman spectroscopy (SERS) | Optical | >8 hours | 0.1 µg/mL HA | [68] |
Hemagglutinin type B | RNA | 28 ± 3 nM | Sedimentation | Optical | >10 minutes | 3.108 VP | [69] |
Hemagglutinin type A | RNA | 1.6 nM | Sedimentation | Optical | >10 minutes | 3.108 VP | [69] |
Hemagglutinin type B | RNA | 0.7 and 1.2 ± 0.2 µg mL−1 | NA | Optical | NA | NA | [33] |
Hemagglutinin H1N1 | DNA | 55.14 ± 22.4 nM | Polymerase chain reaction | Optical | NA | 6.4 × 10−3 HA | [35] |
Rec. Hemagglutinin I H5N1 | DNA | 15.3 nM | Metal-enhanced fluorescence (MEF) | Optical | 30 minutes | 2–3.5 ng/mL | [67] |
Hemagglutinin H1N1 | DNA | NA | Functionalized conductive polymer | Electrochemical | <15 minutes | 103 PFU/mL | [70] |
Human norovirus | |||||||
Capsid protein VP1 | DNA | NA | Surface plasmon resonance (SPR) | Optical | NA | NA | [59] |
Hepatitis C virus | |||||||
Envelop protein E2 | DNA | 1.05 ± 1 nM | Enzyme linked aptamer sorbent assay (ELASA) | Optical | NA | NA | [51] |
Envelop protein E2 | DNA | 0.8–4.0 nM | Enzyme linked aptamer sorbent assay (ELASA) | Optical | NA | 1.25–2.50 × 103 FFU/mL | [47] |
Envelop protein E2 | DNA | 0.8–4.0 nM | Enzyme linked aptamer sorbent assay (ELASA) | Optical | NA | 3.13–6.25 × 102 FFU/mL | [47] |
Helicase | RNA | NA | Microcantilever | Mass | NA | 100 pg/mL | [49] |
Core antigen | DNA | NA | Nucleic acid lateral flow strip | Optical | 10 minutes | 10 pg/mL | [80] |
Core antigen, NS5 | RNA | 100 nM | Sol–gel chips | Optical | NA | NA | [48] |
RNA polymerase | RNA | NA | Microbead-based affinity chromatography chip (µ-BACC) | Mass | NA | 9.6 fmol | [50] |
Core antigen, NS5B | RNA | 6.3 nM | BioLayer Interferometry (BLI) | Optical | NA | 700 pg/mL | [46] |
Hepatitis B | |||||||
Surface antigen | RNA | NA | Fluorescence Resonance Energy Transfer (FRET) | Optical | NA | 1.25 mIU/mL | [61] |
Vaccinia virus | |||||||
Virion | DNA | NA | Surface plasmon resonance (SPR) | Optical | NA | NA | [36] |
Virion | DNA | NA | Electrochemical impedance spectrometry (EIS) | Electrochemical | >1 hour | 330 PFU | [81] |
Dengue virus | |||||||
Genomic nucleic acids | DNA | NA | Fluorescence | Optical | NA | NA | [41] |
Human immunodeficiency virus | |||||||
HIV-1 Tat protein | RNA | NA | Surface plasmon resonance (SPR) | Optical | NA | NA | [52] |
HIV-1 Tat protein | RNA | NA | Quartz crystal microbalance (QCM) | Mass | NA | 0.25 ppm | [52] |
HIV-1 Reverse transcriptase | DNA | NA | Affinity capillary electrophoresis/laser-induced fluorescence (CE/LIF) | Optical | <5 minutes | 50 nM | [54] |
HIV-1 NCp7 | RNA | NA | Solid-state nanopores | Electrochemical | NA | NA | [82] |
HIV-1 Tat protein | RNA | NA | Diamond field-effect transistor (FET) | Electrochemical | NA | 1 nM | [53] |
NA, Not available; VP, Virus particles; HAU, Hemagglutination units; HA, Hemagglutinin; PFU, Plaque-forming units; FFU, Focus-forming units; mIU, milli-international units; ppm, parts per million.